- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00915057
Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.
An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Chronic viral hepatitis B
- Adult, male or female, age ≥ 18 years and < 65 years
- Body weight (BW) : 45 - 110 kg
- Body mass index (BMI) : 18 - 30 kg.m-2
- HBV Serology: HBsAg+ for ≥ 6 months (at the time of application for treatment)
- Serum ALT ≥ 1.5 times ULN ≥ 6 months (at the time of application for treatment)
- Positive liver biopsy within 24 months before screening visit
- Positive biopsy with signs of active disease (any level of activity by Knodell, METAVIR or ISHAK)
- HBV DNA counts determined by quantitative PCR: ≥ 20,000 IU/mL ALT < 10 times ULN
- HIV-Ab negative
- Non-cirrhotic liver disease (on histology within 24 months before screening visit)
- Not having been treated for chronic viral hepatitis previously ("de novo" i.e. "naïve")
- Eligible for treatment of chronic viral hepatitis in accordance with the national consensus guidelines pertinent to the country and site of conduct of the trial
- Willing and able to provide informed consent
Chronic viral hepatitis C
- Adult, male or female, age ≥ 18 years and < 65 years
- Body weight (BW) : 45 - 110 kg
- Body mass index (BMI) : 18 - 30 kg.m-2
- HCV-Ab+ for ≥ 6 months (at the time of application for treatment)
- HCV RNA counts > 10,000 U/L by quantitative PCR assay within the last 6 months (at the time of application for treatment)
- Positive liver biopsy within 24 months before application for treatment
- Positive biopsy with signs of fibrotic disease (levels of fibrosis METAVIR ≥ F1 or ISHAK ≥ F2)
- ALT < 10 times ULN
- HIV-Ab negative
- Non-cirrhotic liver disease (on histology within 24 months before screening visit)
- Not having been treated for chronic viral hepatitis previously ("de novo" i.e. "naïve")
- Eligible for treatment of chronic viral hepatitis in accordance with the national consensus guidelines pertinent to the country and site of conduct of the trial
- Willing and able to provide informed consent
Chronic viral hepatitis C plus chronic viral hepatitis B
- Patients with combined CHB and CHC will be managed (in terms of eligibility and standard treatment in accordance with the hepatitis type with predominant viral replication.
Exclusion Criteria:
Trial specific criteria: CHB, CHC & CHB+CHC
- Previous participation in the trial
- Participation in any other clinical trial within 30 days of entry to this protocol
- Treatment with any investigational drug within 30 days of entry to this protocol
- Non-response to previous treatment for chronic viral hepatitis
- Relapse after previous treatment for chronic viral hepatitis
- Any other known cause of liver disease other than chronic viral hepatitis B and/or C, including but not limited to hepatitis D, haemochromatosis, alpha1-antitrypsin deficiency, Wilson's disease, autoimmune hepatitis, drug-related liver disease
- Evidence of advanced liver disease, such as history or presence of ascites, bleeding varices, encephalopathy
- Patients with organ transplants
- Hypersensitivity to prospective standard treatment
- Any relevant co-morbidity, for instance, but not limited to:
- Limiting uncompensated psychiatric condition (e.g. severe depression, or a history of severe psychiatric disorder)
- CNS trauma or seizure disorder requiring medication
- Significant cardiovascular dysfunction within the past 6 months (e.g. angina, congestive cardiac failure, recent myocardial infarction, severe hypertension or significant arrhythmia)
- Patients with an ECG showing clinically significant abnormalities
- Poorly controlled diabetes mellitus
- Patients on haemodialysis
- Daily use of > 40 g alcohol
- Positive alcohol test at SCR-visit
- Evidence or suspicion of social drug abuse
- Positive drug test at SCR-visit
- Use of prohibited medication
- Suspicion or evidence that the subject is not trustworthy and reliable
- Suspicion or evidence that the subject is not able to make a free consent or to under-stand the information in this regard
Criteria specifically related to the standard treatment of chronic viral hepatitis
- Relevant clinical laboratory test abnormalities, for instance, but not limited to:
Haemoglobin (Hgb) <11 g dL-1 for women and <13 g dL-1 for men
White Blood Cell count (WBC) < 3,000 10 exp9/mL
Granulocyte count < 1,500 10 exp9/mL
Lymphocyte count < 500 10 exp9/mL
Platelets < 75,000 10 exp9/mL
Prothrombin time - INR > 1.4
Bilirubin > 25 micromol/L (except in functional hyperbilirubinaemia)
Albumin < 35 g/L
Serum creatinine > 133 micromol/L
Fasting blood glucose > 7.4 mmol/L for non-diabetic patients
HbA1c > 7% for diabetic patients
Positive auto-immune antibodies
TSH outside the normal range (for patients intended for interferon)
- Relevant co-morbidity, for instance, but not limited to:
Limiting uncompensated chronic pulmonary disease (e.g. chronic obstructive pulmonary disease)
Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids
Gout - (for patients intended for interferon)
Immunologically mediated disease (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis, cryoglobulinaemia with vasculitis) - (for patients intended for interferon)
Patients with clinically significant retinal abnormalities - (for patients intended for interferon)
All females
- Positive pregnancy test
- Lactating
- Not using medically appropriate contraception and/or not willing to maintain such contraception during the treatment of chronic viral hepatitis and up to 6 months thereafter
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: NRL972
Single 2mg intravenous dose of NRL972, administered on up to seven occasions
|
Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Pharmacokinetics of NRL972
Tijdsspanne: Up to one hour post-dosing
|
Up to one hour post-dosing
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NRL972-09/2008 (CHBC)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatitis, viraal, menselijk
-
University of CincinnatiWervingPapillomavirus vaccins | Human Papillomavirus-virussenVerenigde Staten
-
Fundación Pública Andaluza Progreso y SaludGilead SciencesVoltooidHuman Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Co-geïnfecteerde proefpersonenSpanje
-
Centre Hospitalier de CayenneVoltooidHuman Papillomavirus-virussen
-
Nutricia ResearchActief, niet wervendGroei | Tolerantie | Veiligheid | Onderwerpen die behoefte hebben aan een Human Milk Fortifier (HMF)Nederland, Frankrijk, Duitsland, Verenigd Koninkrijk
-
National Taiwan University HospitalWervingHepatitis C-virusinfectie | Hepatitis C-virusinfectie, reactie op therapie van | Human Immunodeficiency Virus (HIV) co-infectieTaiwan
-
Hoffmann-La RocheBeëindigdOestrogeenreceptor-positief (ER+)/Human Epidermal Growth Factor Receptor (HER2)-negatief Lokaal gevorderde of gemetastaseerde borstkankerCanada, Verenigde Staten, Verenigd Koninkrijk, Australië, Duitsland
-
Gilead SciencesVoltooidChronische Hepatitis DeltaFrankrijk, Moldavië, Republiek, Roemenië, Russische Federatie
-
Ziauddin HospitalOnbekend
-
University of Maryland, BaltimoreAlexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... en andere medewerkersBeëindigdAcute hepatitis C | Acute hepatitis B | Acute hepatitis A | Acute hepatitis E | Acute EBV-hepatitis | Acute CMV-hepatitisEgypte
-
National Taiwan University HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanOnbekendChronische hepatitis B | Chronische hepatitis DTaiwan
Klinische onderzoeken op NRL972
-
NorgineVoltooid
-
NorgineVoltooid
-
NorgineVoltooidNiet-alcoholische steatohepatitis | Niet-alcoholische leververvettingVerenigde Staten
-
NorgineVoltooidNiet-alcoholische steatohepatitis | LevercirroseBulgarije
-
NorgineVoltooid
-
Cairo UniversityAhmed Elgazzar HospitalVoltooid